- Home
- MNOV vs ICCM Comparison
MNOV vs ICCM Comparison
Compare MNOV & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- ICCM
- Stock Information
- Founded
- MNOV 2000
- ICCM 2006
- Country
- MNOV United States
- ICCM Israel
- Employees
- MNOV N/A
- ICCM N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- MNOV Health Care
- ICCM
- Exchange
- MNOV Nasdaq
- ICCM Nasdaq
- Market Cap
- MNOV 68.2M
- ICCM 59.9M
- IPO Year
- MNOV 2005
- ICCM N/A
- Fundamental
- Price
- MNOV $1.35
- ICCM $0.89
- Analyst Decision
- MNOV Strong Buy
- ICCM Strong Buy
- Analyst Count
- MNOV 2
- ICCM 1
- Target Price
- MNOV $7.00
- ICCM $2.50
- AVG Volume (30 Days)
- MNOV 49.3K
- ICCM 2.6M
- Earning Date
- MNOV 08-11-2025
- ICCM 08-19-2025
- Dividend Yield
- MNOV N/A
- ICCM N/A
- EPS Growth
- MNOV N/A
- ICCM N/A
- EPS
- MNOV N/A
- ICCM N/A
- Revenue
- MNOV N/A
- ICCM $3,273,000.00
- Revenue This Year
- MNOV N/A
- ICCM $75.27
- Revenue Next Year
- MNOV N/A
- ICCM $129.39
- P/E Ratio
- MNOV N/A
- ICCM N/A
- Revenue Growth
- MNOV N/A
- ICCM 0.34
- 52 Week Low
- MNOV $1.12
- ICCM $0.48
- 52 Week High
- MNOV $2.55
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- MNOV 52.38
- ICCM 34.87
- Support Level
- MNOV $1.32
- ICCM $0.96
- Resistance Level
- MNOV $1.50
- ICCM $1.07
- Average True Range (ATR)
- MNOV 0.07
- ICCM 0.06
- MACD
- MNOV 0.01
- ICCM -0.01
- Stochastic Oscillator
- MNOV 46.43
- ICCM 5.85
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.